When prescribing bevacizumab for high-risk primary ovarian cancer, do you use 15 mg/m2 q 21 days (per GOG-0218) or 7.5 mg/m2 q 21 days (per ICON7)?  

Interesting question. I was told once when bevacizumab was being developed by Genentech that the basic scientists predicted 5 mg/kg would saturate all the VEGF receptors in a typical adult (unconfirmed but told by someone in my remote past...I should confirm with Genentech). How 15 mg/kg was arrived...

When prescribing bevacizumab for high-risk primary ovarian cancer, I use 15 mg/m2 q 21 days per GOG-0218. Based on GOG-0218, this is the FDA-approved dose in this setting. There is limited data on the effect of drug exposure on efficacy or side effects in patients with ovarian cancer who receive bev...

I use 15 mg/kg (please note that bevacizumab dosing is by weight, not per m2) as per GOG-0218. The toxicity is reasonable and the PFS was 4 mo compared to 2 mo for ICON7. Admittedly, likely not a significant difference when comparing across trials, but 15 mg/kg is the standard dose in the US and FDA...